POSTER SESSION III
Tuesday, March 10, 2009 — 9:30 AM - 12:00 Noon
Hynes CC Exhibit Hall C/D
Click on the blue numbers in parentheses to display abstracts.
Click the button next to any title to add to Itinerary Planner...
BREAST PATHOLOGY
Poster#
Title and Authors
Itinerary Planner
26
Androgen Receptor Expression in Ductal Carcinoma In Situ and Its Relationship to Molecular Subtype
(142)
K Cole, R Tamimi, R Hu, G Colditz, S Schnitt, L Collins - Beth Israel Deaconess Medical Center, Harvard Medical School, Harvard School of Public Health, and Brigham and Women's Hospital, Boston, MA; Washington Univ. School of Medicine, St. Louis, MO
Do Clinical and Pathologic Features of Ductal Carcinoma In Situ Vary with Patient Age? An Analysis of 657 Patients
(144)
L Collins, S Schnitt, N Achacoso, S Fletcher, L Nekhlyudov, R Haque, C Quesenberry, L Habel - Beth Israel Deaconess Med Ctr, Boston; Kaiser Permanente Northern California, San Francisco; Harvard Pilgrim Health Care, Boston; Kaiser Permanente Southern California, Los Angeles, CA
Outcome of Women with Ductal Carcinoma In Situ Treated with Breast-Conserving Surgery Alone: A Case-Control Study of 225 Patients from the Cancer Research Network
(143)
L Collins, S Schnitt, N Achacoso, R Haque, L Nekhlyudov, S Fletcher, C Quesenberry, L Habel - Beth Israel Deaconess Med Ctr, Boston; Kaiser Permanente Northern California, San Francisco; Kaiser Permanente Southern California, Los Angeles; Harvard Pilgrim Health Care, Boston, MA
The Incidence of Invasive Carcinoma and Ductal Carcinoma In Situ Following a Core Biopsy Diagnosis of Lobular Neoplasia
(134)
F Chen, C Koenig - New York University School of Medicine, New York, NY; Hackensack University Medical Center, Hackensack, NJ
Evaluation of Connexin 43 and 26 in Intraductal Carcinoma and Their Potential Role in Early Mammary Oncogenesis
(332)
PJ Zhang, TL Pasha, SW Yum, A Geza - Hospital of the University of Pennsylvania, Philadelphia; Drexel University College of Medicine, Philadelphia; Moffitt Cancer Center, Tampa, FL
Lobular Carcinoma In-Situ/Atypical Lobular Hyperplasia on Breast Biopsies: Does It Warrent Surgical Excision?
(265)
M O'Neil, R Madan, O Tawfik, P Thomas, I Damjanov, F Fan - University of Kansas Medical Center, Kansas City, KS
ER/PR Positive and ER/PR Negative DCIS: Morphologic Characterization in a Cohort of Age-Matched Cases
(226)
LP Kunju, CG Kleer - University of Michigan, Ann Arbor, MI
Expression of COX-2, p16, and p53 in Ductal Intraepithelial Neoplasia
(218)
JY Kim, S Sanati, FA Tavassoli - School of Medicine, Pusan National University, Busan, Korea; Yale University School of Medicine, New Haven, CT
Significance of Focal Lobular Neoplasia in Breast Core Needle Biopsy
(158)
SM El Jamal, S Klimberg, R Henry-Tillman, S Korourian - University of Arkansas for Medical Sciences, Little Rock, AR
Lobular Carcinoma In Situ Variants Misinterpreted as Ductal Carcinoma In Situ in Core Biopsy: Incidence and Significance
(308)
ME Sullivan, SA Khan, B Susnik - Northwestern University, Feinberg School of Medicine, Chicago, IL
Mastectomy Offers the Most Effective Local Surgical Control for Ductal Carcinoma In Situ
(307)
K Subik, JM Wang, A Chen, P Ding, P Tai, H Zhang, K Skinner, DG Hicks, P Tang - Univ. of Rochester Medical Center, Rochester, NY; RTI Health Solution, Research Triangle Park, NC
Simulations of Growth of DCIS Parameterized from IHC
(157)
ME Edgerton, YL Chuang, PT Macklin, J Kim, G Tomaiuolo, AD Broom, S Sanga, V Cristini - UT MD Anderson Cancer Center, Houston, TX; UT Houston, Houston, TX; University of Naples, Naples, TX, Italy; University of Texas, Austin, TX
Florid Lobular Intraepithelial Neoplasia with Signet Ring Cells, Central Necrosis and Calcifications: A Clinicopathologic and Immunohistochemical Analysis of Ten Cases
(107)
I Alvarado-Cabrero, R Valencia-Cedillo, S Barroso-Bravo - Mexican Oncology Hospital, Mexico, DF, Mexico
CSF-1 and Fibromatosis Expression in Stroma of Ductal Carcinoma In Situ
(289)
M Sharma, I Espinosa, AH Beck, JA Webster, KD Montgomery, M van de Rijn, KC Jensen, RB West - Stanford University, Palo Alto, CA; Palo Alto Veterans Affairs Health Care System, Palo Alto, CA
Urokinase-Type Plasminogen Activator Is a Marker of Microinvasion in High Grade Ductal Carcinoma In Situ Identified in Core Biopsy
(213)
S Khelifa, B Susnik - Feinberg School of Medicine, Northwestern University, Chicago, IL
Molecular Characterization of DCIS by Immunohistochemistry: Correlation with Histologic Grade, Ki-67, Bcl-2 and p53 Expression
(193)
JS Han, R Ashfaq, Y Peng, VR Sarode - University of Texas Southwestern Medical Center at Dallas, Dallas, TX
HER2 Rabbit Monoclonal Antibody 4B5 and Silver SISH: High Performance in Surgical Pathology for Appropriate Patient Care
(205)
H Itoh, N Kato, A Serizawa, T Itoh, S Umemura, RY Osamura - Tokai University School of Medicine, Isehara, Japan
Clinical Implications of Intra-Tumoral Variation in HER2 Expression in Breast Cancer
(128)
M Bonham, A Lal, S Devries, E Hwang, J Rabban, F Waldman, Y Chen - UCSF, San Francisco, CA
HER2/neu Testing in Breast Carcinoma. Concordance Study Fluorescent In Situ Hybridization vs. Chromogenic In Situ Hybridization
(160)
L Elavathil, B Dhesy, J Wiernikowski, D Browning, N Akhtar-Danesh, W Hanna - McMaster University, Hamilton, ON, Canada; Juravinski Cancer Centre, Hamilton, ON, Canada; Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada
Reliability of Chromogenic In Situ Hybridization for Detecting HER2 Gene Status in Breast Cancer: A Study of Two Institutions Using Manufacturers' Scoring Criteria and the New ASCO/CAP Recommendations
(181)
Y Gong, W Sweet, YJ Duh, L Greenfield, J Zhao, E Tarco, WF Symmans, J Isola, N Sneige - University of Texas M. D. Anderson Cancer Center, Houston, TX; Invitrogen Corporation, Camarillo, CA; StatServ Consulting, Inc., Chino Hills, CA; Institute of Medical Technology, University of Tampere, Tampere, France, Metropolitan
HER2/neu Testing in Breast Cancer, a Reference Centre 8-Year Experience
(334)
JT Zubovits, E Lian, S Nofech-Mozes, W Hanna - Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Canada
HER2 Over-Expression and Histological Features Correlation in Argentinean Breast Cancer Patients
(168)
I Frahm, G Acosta Haab, S Sarancone, V Caceres, HER2 Group - Sanatorio Mater Dei, Buenos Aires, Argentina; Hospital Marie Curie, Buenos Aires, Argentina; Laboratorio Quantum, Rosario, Santa Fe, Argentina; Productos Roche, Tigre, Buenos Aires, Argentina
Evaluation of HER2 Immunostaining in Breast Carcinoma: Use of Image Analysis in Cases with Indeterminate Scores
(327)
C Wynveen, C Hedvat, A Manzo, K Kong, V Barbashina - Memorial Sloan-Kettering Cancer Center, New York, NY
HER2 Status Determined on Pre Operative Biopsies and in Operative Specimens: Concordance among Immunohistochemistry Fluorescence In Situ Hybridization and Chromogenic In Situ Hybridization Techniques in the CRITHER Study
(281)
P Roger, B Lannes, A Balaton, C Hayem, F Campana, L Arnould, F Penault-Llorca, G MacGrogan - Hal Lapeyronie, Montpellier, France; Hal Hautepierre, Strasbourg, France; Centre Pathologie, Bievres, France; Roche, Neuilly sur Seine, France; Centre Leclerc, Dijon, France; Centre Perrin, Clermont-Ferrand, France; Inst. Bergonie, Bordeaux, France
Are FISH HER-2/neu Results the Same on Core Needle Biopsy and Excision in Patients with Breast Cancer?
(236)
AC Lowe, N Rao, P Shintaku, N Moatamed, SK Apple - UCLA, Los Angeles, CA
Immunohistochemical Correlation of p53 with Unamplified Chromosome 17 Polysomy in Invasive Breast Carcinoma
(223)
U Krishnamurti, A Zarineh, F Atem, S Jan - Western Pennsylvania Hospital, Pittsburgh, PA; Allegheny General Hospital, Pittsburgh, PA; University of Pittsburgh, Pittsburgh, PA
Achieving 95% IHC/FISH Concordance for Her2: Causes and Implications of Discordant Cases
(183)
EE Grimm, RA Schmidt, PE Swanson, KH Allison - University of Washington Medical Center, Seattle, WA
Assessments of HER2 Gene Status in Breast Carcinomas with Polysomy of Chromosome 17
(173)
Z Gatalica, S Repertinger, L Hatcher, P Ulmer - Creighton University School of Medicine, Omaha, NE
Hispanic Women Are More Likely To Have HER2 Positive Tumors When Compared to Non-Hispanic White women
(197)
LM Hines, T Byers, B Risendal, SC Mengshol, M Singh - University of Colorado at Colorado Springs, Colorado Springs; UCDHSC, Aurora; Presbyterian Saint Lukes/Unipath 6C, Denver; Stony Brook University Medical Center, Stony Brook
Proliferative Activity and HER-2 FISH Results on Hormone Receptor/HER2 Positive (Luminal Type-B) Breast Cancer
(324)
S White, G Ibrahim, SG Karak, L Mnayer, A Ricci, Jr - Hartford Hospital, Hartford, CT
Validation of the Multiplex Ligand-Dependent Probe Amplification Technique for the Determination of HER2 Gene Amplification in Breast Cancer
(165)
G Farshid, G Cheetham, R Davies, S Moore, B Rudzki - IMVS, South Australian Pathology, Adelaide, SA, Australia
HER2 2+ Breast Cancer in Mexico, Central America and the Caribbean: Re-Testing Results by a Central Lab
(127)
OL Bohn, L Navarro, C Ayaquica, J Saldivar, S Sanchez-Sosa - UPAEP University Hospital, Puebla, Mexico
Refining the Diagnostic Approach in the Evaluation of HER2 in Breast Cancer: A Survey of 2008 Invasive Breast Cancers Comparing a Rabbit Polyclonal Antibody, Rabbit Monoclonal Antibody with Fluorescence In Situ Hybridization
(271)
D Peker, RJ Poppiti, J Alexis, L Howard, E Saiz, H Yaziji - Mt. Sinai Medical Center, Miami Beach, FL; Vitro Molecular Laboratories, Miami, FL
Quantitative Assessment of Her-2 mRNA by PCR in Breast Carcinomas Failing To Hybridize with HER-2 Fish Probes
(126)
KJ Bloom, P Choppa, TA Bloom, A Kyshtoobayeva, M Hibbard - Clarient, Aliso Viejo, CA
Universally-Primed Quantitative Multiplex PCR Short Fluorescent Fragments: A New Detection Method for HER2 Amplification in Breast Cancer
(113)
S Azrak, L Ping, P Starostik, G Wilding, T Khoury - Roswell Park Cancer Institute, Buffalo, NY
Performance of Automated Brightfield Dual Color In Situ Hybridization for Detection of HER2 Gene Amplification in Breast Carcinoma
(260)
H Nitta, B Hauss-Wegrzyniak, M Lehrkamp, A Murillo, M Farrell, M Kurosumi, E Walk, M Dietel, F Penault-Llorca, M Loftus, L Wang, J Pettay, R Tubbs, T Grogan - Roche Ventana Medical Systems, Tucson, AZ; Saitama Cancer Center, Saitama, Japan; Charite-University Medicine Berlin, Berlin, Germany; Centre Jean Perrin, Clermont-Ferrand Cedex, France; Cleveland Clinic, Cleveland, OH
Breast Carcinoma with Positive Lymph Node Status: Assessment of Clinicopathological Variables with Prognostic Implications
(261)
M Niveiro, J Laforga, G Peiro, J Segui, E Adrover, C Alenda, FI Aranda - Universitary General Hospital, Alicante, Spain; General Hospital, Denia, Spain
Comprehensive Sentinel Lymph Node Examination in Ductal-Carcinoma-In-Situ of the Breast: Much Ado about Nothing
(163)
G Falconieri, S Pizzolitto, G DeMaglio - General University Hospital, Udine, Italy
Analysis of Frozen Section Results of Sentinel Lymph Node in 896 Patients with Breast Cancer
(216)
A Kim, WJ Sung, YK Bae, SH Kang, SJ Lee - Yeungnam University College of Medicine, Daegu, Korea
Intraoperative Evaluation of Axillary Sentinel Lymph Nodes Using Touch Imprint Cytology and Rapid Immunohistochemistry
(189)
M Hameed, Q Ahmed, N Uddin, M Tehsin, A Khan, N Sacks - Shaukat Khanum Memorial Cancer Hospital and Research Center, Lahore, Punjab, Pakistan
Predictive Markers in Primary Breast Cancer Compared with Lymph Node and Bloodspread Metastases
(159)
MF El-Sibai, C Cohen, A Nassar, MT Siddiqu - Emory University Hospital, Atlanta, GA; Mayo Clinic, Rochester, MN
Intra-Operative Imprint Cytology of Sentinel Lymph Nodes in Breast Cancer. A Comparison with Conventional H & E and Computer Assisted Image Analysis
(198)
P Horna, R Ashfaq, Y Peng, R Rao, VR Sarode - University of Texas Southwestern Medical Center at Dallas, Dallas, TX
Intraoperative Cytologic Evaluation of Sentinel Lymph Nodes in Breast Cancer: A Community Hospital Experience
(294)
MA Siddiqui, X Chen, VC Lucia, A Ellis, DM Grossman - William Beaumont Hospitals, Troy, MI; William Beaumont Hospitals, Royal Oak, MI
Axilalry Lymph Node Metastatsis in Primary Osteogenic Sarcomas of the Breast
(285)
S Sanati, SY Zaidi, FA Tavassoli - Yale University School of Medicine, New Haven, CT; Sinai Grace Hospital, Detroit Medical Center, Wayne State University, Detroit, MI
Extranodal Extension in Metastatic Axillary Lymph Nodes among Breast Cancer Patients
(233)
Y Li, B Sanchez, AS Godambe, K Albequerque, P Rajan, CH Ersahin - Loyola University Medical Center, Maywood, IL; Radiation Oncology, Maywood, IL
Ultrasound-Guided Needle Core Biopsy of the Axilla Often Samples Sentinel Node
(188)
TT Ha, A Contreras, HA Sattar - University of Chicago, Chicago, IL
Micrometastases in Sentinel Lymph Nodes in Breast Cancer: Clinical Implications
(305)
J Steinmetz, C Ersahin, K Rychlik, A Salhadar, PB Rajan - Chicago Medical School, North Chicago, IL; Loyola University Chicago Medical Center, Maywood, IL
button next to any title to add to Itinerary Planner...
Add
